@article{c8d9d3ef53e945328a1cfb3483fa4670,
title = "The Hi's and Lo's of cytarabine in acute myeloid leukemia",
abstract = "Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.",
author = "Watts, {Justin M.} and Terrence Bradley",
note = "Funding Information: J.M. Watts is supported by the NIH/NCI (5R21CA202488-02) and the Sylvester Cancer Center Support Grant 1P30CA240139-01. Funding Information: J.M. Watts is a paid consultant for Takeda, Rafael Pharma, Genentech, and Jazz Pharma, and reports receiving commercial research grants from Takeda. T. Bradley reports receiving speakers bureau honoraria from Novartis and is a paid consultant/ advisory board member for AbbVie. No other potential conflicts of interest were disclosed. Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",
year = "2020",
month = jul,
doi = "10.1158/1078-0432.CCR-20-0462",
language = "English (US)",
volume = "26",
pages = "3073--3076",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",
}